{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:56:34Z","timestamp":1778270194952,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.amjcard.2018.02.021","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T13:17:16Z","timestamp":1519996636000},"page":"1393-1399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-9934","authenticated-orcid":false,"given":"Aiman","family":"Smer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsin","family":"Salih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toufik","family":"Mahfood Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raviteja","family":"Guddeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulghani","family":"Saadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Saurav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Belbase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Traina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata","family":"Alla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Del Core","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2018.02.021_bib0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: heart disease and stroke statistics\u20132016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0015","first-page":"1","article-title":"Hospitalization for stroke in U.S. hospitals, 1989\u20132009","author":"Hall","year":"2012","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0020","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ene.12673","article-title":"Cryptogenic stroke","volume":"22","author":"Fonseca","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0025","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.amjcard.2006.12.054","article-title":"Five-year experience with percutaneous closure of patent foramen ovale","volume":"99","author":"Slavin","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0002-9149(93)90518-H","article-title":"Relation between patent foramen ovale and unexplained stroke","volume":"71","author":"Van Camp","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjcard.2016.09.026","article-title":"Overview of the 2016 US Food and Drug Administration Circulatory System Devices panel meeting on the amplatzer patent foramen ovale occluder","volume":"119","author":"Rogers","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0040","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0045","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.cjca.2014.05.004","article-title":"Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses","volume":"30","author":"Udell","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0055","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"Sondergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0065","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-2-1","article-title":"Simpson's paradox and calculation of number needed to treat from meta-analysis","volume":"2","author":"Cates","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0080","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa1009639","article-title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","volume":"366","author":"Furlan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","article-title":"Percutaneous closure of patent foramen ovale in cryptogenic embolism","volume":"368","author":"Meier","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0090","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","article-title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","volume":"368","author":"Carroll","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0095","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjcard.2014.12.051","article-title":"Meta-analysis of net long-term benefit of different therapeutic strategies in patients with cryptogenic stroke and patent foramen ovale","volume":"115","author":"Patti","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0100","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMe1201173","article-title":"Patent foramen ovale closure\u2014closing the door except for trials","volume":"366","author":"Johnston","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0105","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJMoa011503","article-title":"Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both","volume":"345","author":"Mas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijcard.2016.01.185","article-title":"Randomized trials of closure of persistent foramen ovale (PFO) vs medical therapy for patients with cryptogenic stroke\u2014effect of lost-to-follow-up and withdrawal of consent","volume":"207","author":"Dellborg","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/01.CIR.101.8.893","article-title":"Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events","volume":"101","author":"Windecker","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0120","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.57.7.1330","article-title":"Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism","volume":"57","author":"Wahl","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2008.02.031","article-title":"Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: difference in occlusion systems and influence of atrial septum aneurysm","volume":"134","author":"von Bardeleben","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0130","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/ehv252","article-title":"Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis","volume":"36","author":"Kent","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0135","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jacc.2015.12.023","article-title":"Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials","volume":"67","author":"Kent","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ccd.26518","article-title":"Long-term follow-up after PFO device closure: outcomes and complications in a single-center experience","volume":"89","author":"Taggart","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0145","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.amjcard.2008.05.045","article-title":"Incidence of atrial fibrillation following transcatheter closure of atrial septal defects in adults","volume":"102","author":"Spies","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.02.021_bib0150","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ccd.22172","article-title":"New onset atrial fibrillation after patent foramen ovale closure","volume":"74","author":"Staubach","year":"2009","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918302571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918302571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T13:51:06Z","timestamp":1535032266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914918302571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0002914918302571"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.02.021","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}